Royalty Pharma plc was incorporated under the laws of England and Wales on 6 February 2020. The company is the largest buyer of biopharmaceutical royalties and a major funder of innovation in the biopharmaceutical industry. Since its inception in 1996, the company has been a pioneer in the royalty market, partnering with innovators from academic institutions, research hospitals and non-profit organizations (from small and medium-sized biotech companies to leading global pharmaceutical companies). The company collects a series of royalties that entitle them to make payments directly based on top-line sales of many industry-leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri and Xtandi. The company directly or indirectly funds innovation in the biopharmaceutical industry when they partner with companies to co-finance late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when they receive existing royalties from original innovators.
